Topical Oil and Soft Gel

OleiaTopical Oil and Soft gel contrails Cetylated Fatty Acid (or cetyl myristoleate)and is a natural substance which helps those who are suffering from arthritis and auto-immune disorders associated with deficiency in Essential Fatty Acids. Cetyl Myristoleate is an ester of fatty acid.

Fatty acids are the individual components of oils in the same way that amino acids are the building blocks of proteins. Polyunsaturated fatty acids, such as linotenic acid and linolelic acid, are crucial to life and are called Essential Fatty Acids (EFAs).

EFAs are essential to normal cell structure, physiological processes, body function, and function as components to nerve cells and cell membranes.
EFAs are depleted in chronic inflammatory diseases and their deficiency is associated with many autoimmune diseases.
EFAs when used over an extended period of time have been shown to decrease pain, inflammation, and motion limitations of arthritis.
Research has shown that cetyl myristoleate appears to have the same beneficial characteristics as the EFAs, however, it is stronger and the benefits are longer lasting. It offers the same benefits of decreasing pain and inflammation, but at a relatively faster time span offering quicker relief to pain.


• Functions like a fatty acid in that it mediates inflammatory processes.
• serves as a surfactant like WD-40 as it lubricates not only the involved joints, but also lubricates the entire body, making muscles glide more smoothly over other muscles, bursas, and bones and at the same time softens these tissues making them more pliable.
• Functions as an immune system modulator. This is the reason it has been found to be so effective in addressing auto-immune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.


Cetyl myristoleate is presently being used by integrative medical practitioners to address many inflammatory conditions, including tendonitis; rheumatoid and osteoarthritis; psoriasis and psoriatic arthritis and muscle tension headaches. The one symptom common to most disease process at one state or another is inflammation. Inflammation is a normal response by the body to injury, and functions as part of the healing process. It becomes a problem, however, when it's uncontrolled and starts to produce more tissue damage.

To really understand how cetyl myristoleate works, we need to know a little bit about prostaglandins and leukotrienes.

Prostaglandins are not only important in regulation of inflammation, pain, and swelling, they also help to regulate blood pressure, heart function and pancreatic hormone functions.

Prostaglandins fall into three categories. Series 1 and 3 prostaglandins are the favorable or good prostaglandins; and prostaglandins Series 2 are considered the unfavorable ones. For instance, prostaglandins of the second series cause increased inflammation, induce constriction of blood vessels, and promote platelet stickiness. And as inflammation increases within damaged tissues, swelling and pain increase along with the chance of further damage by cutting off normal blood supply. In contrast, prostaglandins of the first and third series reduce inflammation, prevent the platelets from sticking together, and improve blood flow.
By using cetyl myristoleate, you can manipulate prostaglandin metabolism, making sure that the good prostaglandins are in abundance and the bad prostaglandins are kept at a minimum.

Leukotrienes are like prostaglandins in that they are chemical mediators of inflammation. Leukotrienes cause smooth muscle contraction in blood vessels and bronchial airways, and they also cause increased permeability in the blood vessels which results in edema or swelling of tissues.
One possible explanation of Cetyl ability to mediate an immune system that is attacking its own tissues and causing an auto-immune disease is the inhibition of leukotriene B4 production.
Leukotriene B4 is a compound that has potent chemotactic activity for certain phagocytic cells. These phagocytic cells normally ingest and destroy substances such as bacteria, protozoa, cells and cellular debris, but in auto-immune disorders they start to attack and ingest healthy tissues.
In other words, Leukotriene B4 sends out a message to these phagocytic cells which affect their ability to differentiate the "good guys" from the "bad guys," telling them to "come here quickly." Suddenly, in one location, we have a whole bunch of Pac-Man-like activity eating up healthy tissues!
Leukotrienes are responsible for producing many of the symptoms related to allergic reactions.
Inhibiting leukotriene production may be one of the explanations for Cetyl myristoleate's far-reaching results.


Oleia Soft gel is best used to address

  • All types of arthritis:
  • Rheumatoid arthritis
  • Osteoarthritis
  • Gouty arthritis
  • Inflammatory conditions:
  • Tendonitis
  • Tension headaches
  • Migraine
  • Sports injuries
  • Tennis-golfer's elbow
  • Bronchitis asthma
  • Tonsillitis
  • Sinusitis
  • Gastritis
  • Frozen shoulder
  • Wrist pain (carpal tunnel syndrome)
  • Neck pain
  • Back pain
  • Prostate inflammation
  • Cardiovascular conditions:
  • Hypertension
  • (High blood pressure)
  • Autoimmune disorders:
  • Hypo/ hyper-thyroids
  • Lupus
  • Multiple sclerosis


Oleia Soft gel is safe and natural.

It is manufactured in the United States following strict quality assurance standards of the USFDA and in compliance with the Good Manufacturing Practices (GMP) quality control guidelines.


Improves mobility in patients with osteo arthritis of the knee and may be a safer alternative to the use of non steroidal anti-inflammatory drugs for the treatment of osteoarthritis.
Has shown to offer significant benefits in the prevention of arthritic episodes among individuals with various autoimmune diseases.
Cetyl myristoleate effectively reduce moderate inflammatory pain levels in variety of joint and muscle diseases. It reduces disability related to migraine headaches and psoriasis and has broad-spectrum anti-inflammatory and analgesic applications.
Effective for improving knee range of motion, ability to climb stairs, rise from a chair and walk; and improving balance, strength and endurance in patients with osteoarthritis.
Cetyl myristoleate may help the exercise-trainability of people with osteoarthritis.
Induces apoptosis and necrosis (cell death) in human prostates (prostate) cells.

Cetylated fatty acid (cetyl myristoleate) is bioavailable, meaning it is 100% absorbed in the intestinal mucosa. It is well absorbed when given orally or topically.


On the first month, take 60 softgels: 2 soft gels a day for 30 days: one soft gel before lunch and one softel before bedtime. After the loading dose of 60 softgels, take One (1) softgel a day.

For best results, also apply Oleia Oil topical around aching joints or sore muscles.


Refrain from smoking and drinking carbonated beverages, citrus juice and caffeine as these may interfere with absorption. Avoid concomitant use with steroids and alcohol.


NOTE: Cetylated fatty acid in OLEIA Oil contains myristoleic acid.

1. Anti- Pancreatic Cancer Effects of Myristoleic Acid

X.Z. Ding, R. Witt, W.G. Tong, X.Q. Li, H. Betts, P. Collin, T.E. AdrianDepartment of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA


We have previously shown that certain lipid fractions of a commercial extract of the sea cucumber, Cucumaria frondosa have potent anti-pancreatic cancer activity. We have now identified myristoleic acid as a component of one extract that exhibits anticancer activity and lipoxygenase inhibitory activity. The current study was designed to characterize the effects of myristoleic acid, a Monounsaturated fatty acid, in pancreatic cancer.

Materials and Methods:

Cellular proliferation and apoptosis were evaluated by thy-midline incorporation, TUNEL assay and annexin V binding in different cell lines. The in vivo effects of myristoleic acid were tested on human pancreatic cancer xenografts in athymic mice.


Myristoleic acid

(1) abolishes proliferation of pancreatic cancer cells in vitro
(2) induces apoptosis in vitro
(3) markedly inhibits growth of pancreatic cancers xenografted into athymic mice
(4) induces apoptosis in pancreatic cancers in vivo.


Myristoleic acid, a natural fatty acid component of a commercial seacucumber lipid product, has potent anti-proliferative effects on human pancreaticcancer with induction of apoptosis. This fatty acid may be valuable for the treatmentand prevention of pancreatic adenocarcinoma and is currently undergoing preclinical development.

June 2004 Klaus Brill, M.D., Principal Investigator, Neuronet Institute, St. Wendel,
Germany David Eckes, M.D., Secondary Investigator, Private Practice, Hastings, MN, USA
Elmar Weiler, PhD, Neuronet Institute, St. Wendel, Germany Gary Lord, Principal Coordinating Investigator, Sierra Life Sciences, Inc., Reno, NV, USA


In this open-label study using Omega-5 (Cetyl Myristoleate) was administered orally to Seventy-one patients suffering from various pain symptoms from a variety of issues. Ninety-two percent of the patients showed marked reduction of pain and inflammation when treated with Omega-5.

All patients had a history of pain treatment with conventional pharmaceutical agents, herbal agents, physical therapy, or a combination of these treatment choices. Patients were not asked to discontinue the use of their existing any medications but rather were asked to report any improvements in their conditions and reductions in their medications as they used Omega-5.

Thirty-five of the patients in this study presented themselves to the pain clinic, "Neuronet Institute, Klaus Brill, M.D., director." located in St. Wendel, Germany and the balance of

Osteoarthritis/Rheumatoid Arthritis:

55 patients had an average starting pain level of 5.2. Following enteric-coated Omega-5 treatment their average "study completed pain level" was 1.4 representing a drop of 3.8 from the 5.2 levels. That is an average 73% reduction in pain level.

Fibromyalgia: 8 patients had an average starting pain level of 5.8. Following enteric-coated omega-5 treatment their average "study completed pain level" was 0.8 representing a drop of 5.0 from the 5.8 levels. That is an average 86% reduction in pain level. Repetitive stress injuries: 5 patients had an average starting pain level of 5.6. Following enteric-coated Omega-5 treatment their average "study completed pain level" was 0.8. That is an average 85% reduction in pain level.

Psoriasis/dermatitis: 2 patients entered the study. One patient was a non-responder and left the study. One patient entered the study without pain, but a cosmetic level of 7 was issued on admission for his psoriasis condition. Following combined use of enteric-coated Omega-5 capsules and lotion the patient reported significant improvement in the flaking, itching, and overall appearance of psoriatic plaques on the skin's surface. The final rating in the cosmetic features was graded at 1.

Migraine headache: 1 patient reported that the frequency of migraines headaches and the intensity of the headache pain were at a 7 level before taking a therapeutic dose of enteric-coated Omega-5. Frequency and intensity of headache pain levels dropped to a level of 1 following the treatment program.

Analysis of the study's results shows the following:

Of the 71 patients initially entered into the study, 4 were non-responders, and one was eliminated because of a presumed side effect. That is, 5/71 or 7% did not finish the study. The remaining 66 patients responded favorably to a 12-week program of Omega-5 treatment, a positive response rate of 92%. If we group together all 66 responding patients with pain complaints, (i.e. the patients with OA/RA, fibromyalgia, repetitive stress injury, and migraine) the average entry level of pain was 5.4. The average exit level of pain was 1.3. The drop of 4.1 in pain level were classified as non-responders and did not complete the study. "CHIPCO5" verifies that Omega-5 has broad-spectrum anti-inflammatory and analgesic applications.

3. Cetylated Fatty Acids Improve Knee Function in Patients with Osteoarthritis

J Rheumatol 2002; 29:1708-12



To determine the benefit of cetylated fatty acids (CFA) on knee range of motion and function in patients with osteoarthritis (OA).


Sixty-four patients with chronic knee OA were evaluated at baseline and at 30 and 68 days aft consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n = 33). Evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI).


After 68 days, patients treated with CFA exhibited significant (p < 0.001) increase in knee flexio (10.1°) compared to patients given placebo (1.1°). Neither group reported improvement in knee extension. Patient responses to the LAI indicated a significant (p < 0.001) shift towards functional improvement for the CFA group (-5.4 points) after 68 days compared to a modest improvement in the placebo group (-2.1 points).


Compared to placebo, CFA provides an improvement in knee range of motion and overall function in patients with OA of the knee. CFA may be an alternative to the use of nonsteroidal anti-inflammatory drug for the treatment of OA.

From Hesslink Ventures and ClinCyte, San Diego, California, USA, and the Medical Center, Manipal, India. Supported in part by a research contract awarded to ClinCyte by Imagenetix, Inc., San Diego, CA, USA. R. Hesslink Jr, ScD; D. Armstrong III, PhD, Hesslink Ventures; M.V. Nagendran, MD, Medical Center, Manipal; S. Sreevatsan, PhD; R. Barathur, PhD, ClinCyte.

Address reprint requests to Dr. R. Hesslink Jr, PO Box 501691, San Diego, CA 92150. Submitted July 27, 2001; revision accepted February 14, 2002.

4. Myristoleic acid induces death of prostate cancer cells.

A study conducted in Gifu Pharmaceutical University in Japan showed that myristoleic acid may be used in the treatment of prostate cancer.

Clinical Study

Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.
Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K.
Laboratory of Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan.


Prostatic tumors are well known to progress to hormonal therapy-resistant terminal states. At this stage, there are no chemotherapeutic agents to affect clinical outcome. An effective cell death inducer for these prostate cells may be a candidate as an attractive antitumor agent. The extracts from S. repens have been used to improve the state of prostatic diseases and we have attempted to identify the effective component from the extract. METHODS: Cell viability was examined in LNCaP cells, an in vitro model for hormonal therapy-resistant prostatic tumor. RESULTS:

We found that exposure of the extract from S. repens resulted in cell death of LNCaP cells. We also identified myristoleic acid as one of the cytotoxic components in the extract. The cell death exhibited both apoptotic and necrotic nuclear morphology as determined by Hoechst 33342 staining. Cell death was also partially associated with caspase activation.


It was demonstrated that the extract from S. repens and myristoleic acid induces mixed cell death of apoptosis and necrosis in LNCaP cells. These results suggest that the extract and myristoleic acid may develop attractive new tools for the treatment of prostate cancer.


5. Anti-inflammatory properties of Moringa Oleifera

There are over 46 antioxidants and 36 anti-inflammatory compounds all naturally occurring in the Moringa plant.

Vitamin A, Vitamin C, Vitamin E, Vitamin K, Vitamin B (Choline), Vitamin B1 (Thiamin), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Alanine, Alpha-Carotene, Arginine, Beta-Carotene, Beta-sitosterol, Caffeoylquinic Acid, Campesterol, Carotenoids, Chlorophyll, Chromium, Delta-5-Avenasterol, Delta-7-Avenasterol, Glutathione, Histidine, Indole Acetic Acid, Indoleacetonitrile, Kaempferal, Leucine, Lutein, Methionine, Myristic-Acid, Palmitic-Acid, Prolamine, Proline, Quercetin, Rutin, Selenium, Threonine, Tryptophan, Xanthins, Xanthophyll, Zeatin, Zeaxanthin, Zinc.

Vitamin A, Vitamin B1 (Thiamin), Vitamin C, Vitamin E, Arginine, Beta-sitosterol, Caffeoylquinic Acid, Calcium, Chlorophyll, Copper, Cystine, Omega 3, Omega 6, Omega 9, Fiber, Glutathione, Histidine, Indole Acetic Acid, Indoleacetonitrile, Isoleucine, Kaempferal, Leucine, Magnesium, Oleic-Acid, Phenylalanine, Potassium, Quercetin, Rutin, Selenium, Stigmasterol, Sulfur, Tryptophan, Tyrosine, Zeatin, Zinc.

6. DOST Study: Anti-inflammatory and Antitumor Activities of Seeds Extracts of Malunggay, Moringa oleifera L. (Moringgaceae)

Amelia P. Guevara, Carolyn Vargas and Milagros Uy


The seeds of malunggay, Moringa oleifera, were extracted with distilled ethanol and concentrated under reduced pressure at 40oC. The resulting extract was partitioned between hexane, ethylacetate, butanol and water. The solvent fractions were likewise concentrated under reduced pressure.

The crude ethanol extract of dried seeds inhibited the carrageenan-induced inflammation in the hind paw of mice by 85% at a dosage of 3 mg/g body weight while the mature green seeds by 77% The hexane fraction of the crude ethanol extract of the dried seeds also inhibited inflammation by 77% at the same dosage while both butanol and water fractions inhibited inflammation by only 34% These results indicate the strong anti-inflammatory activities of the ethanol extract and the hexane fraction.

On the other hand, the ethylacetate fraction caused a 267% increase in inflammation and exhibited toxicity. The mice died after oral administration of the fraction. The crude ethanol extract also inhibited the formation of Epstein-Barr virus-early antigen (EBV-EA) induced by 12-0-tetradecanoylphorbol-13-acetate (TPA). At a dosage of 100? g/ml, the extract inhibited EBV-EA formation by 100% suggesting its antitumor-promoting activity.

7. PUBMED: Anti-inflammatory activity of Moringa oleifera (moringaceae)]
Ndiaye M, Dieye AM, Mariko F, Tall A, Sall Diallo A, Faye B.

Laboratoire de Pharmacologie et de Physiologie, UCAD, BP 5005,Dakar, Seregal.

Moringa oleifera is a bush of African savannah, used in folk Medicine for the treatment of rheumatic and articulary pain. We have tested the anti-inflammatory action of an aqueous extract of root in rats with weight between 120 and 160 g. We administered per os either distilled water (control group), the aqueous root extract (750 mg/kg or 1000 mg/kg) or indomethacin (10 mg/kg) 30 min before an oedema was induced in the rat-paw by subcutaneous injection of carrageenin.

The rat-paw volume was measured 1, 3 and 5 hours after injection of carrageenin. At a dose of 750 mg/kg the Moringa oleifera treatment significantly inhibited the development of oedema at 1, 3 and 5 hours (reduction by 53.5, 44.6 and 51.1% respectively). Increasing the dose of Moringa oleifera to 1000 mg/kg did not increase the inhibitory effect on oedema development at 1 and 3 hours, whereas this dose potentiated the oedema at 5 hours.

Treatment with indomethacin significantly inhibited the development of oedema 1, 3 and 5 hours (49.1, 82.1 and 46.9% respectively). These findings indicate that an aqueous root extract of Moringa oleifera at 750 mg/kg reduces the carrageenin induced oedema to similar extent as the potent anti-inflammatory drug indomethacin. Moreover, these results provide further evidence that the roots of Moringa oleifera contain anti-inflammatory principle that may be useful in the treatment of the acute inflammatory conditions.

PMID: 15776678 [PubMed - indexed for MEDLINE]

8. PUBMED: Antiinflammatory effects of Moringa oleifera root extract

EZEAMUZIE I. C.; AMBAKEDEREMO A. W.; SHODE F. O. ; EKWEBELEM S. C.; Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat, 13110, KOWEIT

Résumé / Abstract

A crude methanol extract of the root of the plant Moringa oleifera Lam. was screened for anti inflammatory effect using the rat paw edema and the rat 6-day air pouch inflammatory models. Following oral administration, the extract inhibited carrageenan-induced rat paw edema in a dose-dependent manner, with 50% inhibitory concentration - IC [50] (dose producing 50% inhibition) of 660 mg/kg. On the 6-day air pouch acute inflammation induced with carrageenan, the extract was much more potent, with IC [50] values of 302.0 mg/kg and 315.5 mg/kg, for the inhibition of cellular accumulation and fluid exudation, respectively. Maximum inhibition obtained with 600 mg/kg were 83.8% and 80.0%, respectively. When delayed (chronic) inflammation was induced in the 6-day air pouch model using Freund's complete adjuvant, the extract was still effective though less than in acute inflammation. In contrast a moderate dose of indomethacin (5 mg/kg) inhibited the acute, but not the delayed form of air pouch inflammation. Acute toxicity tests in mice suggest very low toxicity. These results suggest that the root of Moringa oleifera contains anti inflammatory principle(s) that may be useful in the treatment of both the acute and chronic inflammatory conditions.

9. Analgesic, anti-inflammatory and local anaesthetic activity of Moringa in laboratory animals

MEDHI Bandana; KHANIKOR H. N.; LAHON L. C.; MOHAN P.; BARUA C. C.;Department of Pharmacology and Toxicology, College of Veterinary Science, Guwahati, Assam, INDE

Revue / Journal Title International journal of pharmacognosy (Int. j. pharmacogn.) 1996, vol. 34, no3, pp. 207-212

Résumé / Abstract

The methanol extract of Moringa (Moringaceae) was used to evaluate its analgesic, anti-inflammatory and local anaesthetic activity in the present study. Analgesic activity was tested in mice using various doses orally. Acetic acid-induced writhing episodes were significantly and dose-dependently reduced. At the same dose, its anti-inflammatory activity was also tested. Carrageenin (a standard inflammatory agent)-induced paw edema in mice was significantly reduced after oral administration. Furthermore, its local anaesthetic activity were tested in frog and guinea pig models, and it was seen that in both animals, the plant (root bark) produces significant local anaesthetic activity.

Revue / Journal Title Pharmaceutical biology (Pharm. biol.) ISSN 1388-0209

Source / Source 2003, vol. 41, no4, pp. 248-252 [5 page(s) (article)] (7 ref.)